120 related articles for article (PubMed ID: 33517265)
21. Potential association of LOXL1 with peritoneal dissemination in gastric cancer possibly via promotion of EMT.
Hu Q; Masuda T; Kuramitsu S; Tobo T; Sato K; Kidogami S; Nambara S; Ueda M; Tsuruda Y; Kuroda Y; Ito S; Oki E; Mori M; Mimori K
PLoS One; 2020; 15(10):e0241140. PubMed ID: 33095806
[TBL] [Abstract][Full Text] [Related]
22. GM130 regulates epithelial-to-mesenchymal transition and invasion of gastric cancer cells via snail.
Zhao J; Yang C; Guo S; Wu Y
Int J Clin Exp Pathol; 2015; 8(9):10784-91. PubMed ID: 26617790
[TBL] [Abstract][Full Text] [Related]
23. C-C motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy.
Wei Y; Wang T; Song H; Tian L; Lyu G; Zhao L; Xue Y
J Surg Res; 2017 May; 211():266-278. PubMed ID: 28501127
[TBL] [Abstract][Full Text] [Related]
24. Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer: clinical implications for prognosis and peritoneal recurrence.
Yoo C; Ryu MH; Park YS; Yoo MW; Park SR; Ryoo BY; Jang SJ; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2015 Sep; 22(9):2940-7. PubMed ID: 25605515
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of
Shimizu D; Saito T; Ito S; Masuda T; Kurashige J; Kuroda Y; Eguchi H; Kodera Y; Mimori K
Cancer Genomics Proteomics; 2018; 15(4):313-320. PubMed ID: 29976636
[TBL] [Abstract][Full Text] [Related]
26. Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
Yamaguchi H; Satoh Y; Ishigami H; Kurihara M; Yatomi Y; Kitayama J
Ann Surg Oncol; 2017 Oct; 24(11):3345-3352. PubMed ID: 28726078
[TBL] [Abstract][Full Text] [Related]
27. Monitoring with sensitive tumor markers contributes to decision-making and better prognosis in gastric cancer patients with peritoneal recurrence.
Ohashi T; Komatsu S; Ichikawa D; Kosuga T; Okamoto K; Arita T; Konishi H; Morimura R; Murayama Y; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Fujiwara H; Otsuji E
Int J Clin Oncol; 2017 Oct; 22(5):897-904. PubMed ID: 28488013
[TBL] [Abstract][Full Text] [Related]
28. Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer.
Hu Q; Masuda T; Sato K; Tobo T; Nambara S; Kidogami S; Hayashi N; Kuroda Y; Ito S; Eguchi H; Saeki H; Oki E; Maehara Y; Mimori K
Ann Surg Oncol; 2018 Mar; 25(3):745-753. PubMed ID: 29270876
[TBL] [Abstract][Full Text] [Related]
29. PLOD2 as a potential regulator of peritoneal dissemination in gastric cancer.
Kiyozumi Y; Iwatsuki M; Kurashige J; Ogata Y; Yamashita K; Koga Y; Toihata T; Hiyoshi Y; Ishimoto T; Baba Y; Miyamoto Y; Yoshida N; Yanagihara K; Mimori K; Baba H
Int J Cancer; 2018 Sep; 143(5):1202-1211. PubMed ID: 29603227
[TBL] [Abstract][Full Text] [Related]
30. Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test.
Yamashita K; Ushiku H; Katada N; Hosoda K; Moriya H; Mieno H; Kikuchi S; Hoshi K; Watanabe M
Eur J Surg Oncol; 2015 Oct; 41(10):1324-32. PubMed ID: 26251341
[TBL] [Abstract][Full Text] [Related]
31. Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis.
Hao Y; Liu Y; Ishibashi H; Wakama S; Nishino E; Yonemura Y
Eur J Surg Oncol; 2019 Aug; 45(8):1493-1497. PubMed ID: 30948161
[TBL] [Abstract][Full Text] [Related]
32. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
Stiekema J; Trip AK; Jansen EP; Boot H; Cats A; Ponz OB; Verheij M; van Sandick JW
Ann Surg Oncol; 2014 Apr; 21(4):1107-14. PubMed ID: 24306660
[TBL] [Abstract][Full Text] [Related]
33. Homeobox C10 Influences on the Malignant Phenotype of Gastric Cancer Cell Lines and its Elevated Expression Positively Correlates with Recurrence and Poor Survival.
Miwa T; Kanda M; Umeda S; Tanaka H; Tanaka C; Kobayashi D; Suenaga M; Hayashi M; Yamada S; Nakayama G; Koike M; Kodera Y
Ann Surg Oncol; 2019 May; 26(5):1535-1543. PubMed ID: 30673899
[TBL] [Abstract][Full Text] [Related]
34. Up-regulated Wnt1-inducible signaling pathway protein 1 correlates with poor prognosis and drug resistance by reducing DNA repair in gastric cancer.
Zhang LH; Wang Y; Fan QQ; Liu YK; Li LH; Qi XW; Mao Y; Hua D
World J Gastroenterol; 2019 Oct; 25(38):5814-5825. PubMed ID: 31636474
[TBL] [Abstract][Full Text] [Related]
35. FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer.
Tanaka H; Kanda M; Shimizu D; Tanaka C; Kobayashi D; Hayashi M; Iwata N; Yamada S; Fujii T; Nakayama G; Sugimoto H; Fujiwara M; Niwa Y; Kodera Y
Ann Surg Oncol; 2017 Oct; 24(11):3438-3445. PubMed ID: 27770343
[TBL] [Abstract][Full Text] [Related]
36. TPX2 expression is associated with poor survival in gastric cancer.
Tomii C; Inokuchi M; Takagi Y; Ishikawa T; Otsuki S; Uetake H; Kojima K; Kawano T
World J Surg Oncol; 2017 Jan; 15(1):14. PubMed ID: 28069036
[TBL] [Abstract][Full Text] [Related]
37. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
38. The utility of high-mobility group A2 overexpression for predicting the prognosis of gastric cancer patients and its contribution to poor prognosis via chemoresistance and the propensity for the occurrence of carcinomatosis peritonei.
Lee H; Lee HH; Lim CY; Lee J
Surgery; 2021 May; 169(5):1213-1220. PubMed ID: 33376002
[TBL] [Abstract][Full Text] [Related]
39. Transcriptomic profiling on localized gastric cancer identified CPLX1 as a gene promoting malignant phenotype of gastric cancer and a predictor of recurrence after surgery and subsequent chemotherapy.
Tanaka H; Kanda M; Shimizu D; Tanaka C; Inokawa Y; Hattori N; Hayashi M; Nakayama G; Kodera Y
J Gastroenterol; 2022 Sep; 57(9):640-653. PubMed ID: 35726075
[TBL] [Abstract][Full Text] [Related]
40. Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial.
Yang HK; Ji J; Han SU; Terashima M; Li G; Kim HH; Law S; Shabbir A; Song KY; Hyung WJ; Kosai NR; Kono K; Misawa K; Yabusaki H; Kinoshita T; Lau PC; Kim YW; Rao JR; Ng E; Yamada T; Yoshida K; Park DJ; Tai BC; So JBY;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):120-127. PubMed ID: 33253659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
